ARTICLE | Company News
XTL, Biostapro antibody deal
October 12, 2001 7:00 AM UTC
XTL Biopharmaceuticals (LSE:XTL) licensed from Biostapro (Uppsala, Sweden) two cell surface targets expressed in staphylococcal bacteria S. aureus and S. epidermidis. The companies will develop human ...